We represent plaintiffs and direct purchasers of Suboxone in this class action alleging that the seller of that brand drug engaged in a multi-part scheme to illegally delay generic competition for Suboxone. Plaintiffs allege that the scheme included the brand manufacturer coercing a market shift from Suboxone tablets to a new version of Suboxone that offered no clinical benefits, and engaging in other acts intended to prevent or delay less expensive generic versions of Suboxone from entering the market. We are seeking to recover overcharges on behalf of a class of direct purchasers under the federal antitrust laws. The court upheld most of plaintiffs’ claims after defendants filed a motion to dismiss the case, and the parties are engaged in discovery.